Table 3.
Determinants of failure to find patients with Kaposi sarcoma who were lost to follow-up in four countries in sub-Saharan Africa. Sample is limited to patients who gave consent for tracking and who had sufficient information to attempt physical tracking (n = 354)
| Unadjusted | Adjusteda | |||
|---|---|---|---|---|
| Risk Ratio (95% CI) | P value | Risk Ratio (95% CI) | P value | |
| Age at last visit, per 1 year increase | 0.98 (0.95–1.01) | 0.21 | 1.0 (0.97–1.03) | 0.87 |
| Sex | ||||
| Women | Ref. | Ref. | ||
| Men | 0.72 (0.42–1.23) | 0.23 | 0. 59 (0.35–1.01) | 0.055 |
| Duration of being lost at database closure, per 1 month increase | 1.03 (1.02–1.05) | <0.001 | 0.99 (0.98–1.01) | 0.48 |
| Duration since KS diagnosis at last visit, per 1 month increase | 0.96 (0.90–1.02) | 0.19 | 0.94 (0.89–1.00) | 0.065 |
| ART in use at last visit | ||||
| Not on ART | Ref. | Ref. | ||
| On ART | 0.40 (0.24–0.68) | 0.001 | 0.68 (0.40–1.14) | 0.144 |
| Site | ||||
| AMPATH-Kenya | Ref. | Ref. | ||
| ISS-Mbarara | 8.5 (3.8–19.1) | <0.001 | 9.7 (4.2–22.2) | <0.001 |
| Lighthouse-Malawi | 10.5 (4.5–24.5) | <0.001 | 12.1 (4.9–29.9) | <0.001 |
| UATH & NHA-Nigeria | 6.6 (2.3–19.3) | <0.001 | 8.7 (2.8–26.6) | <0.001 |
ART denotes antiretroviral therapy; AMPATH denotes Academic Model Providing Access to Healthcare in western Kenya; ISS denotes Immune Suppression Syndrome Clinic in Mbarara, Uganda; UATH denotes University of Abuja Teaching Hospital in Abuja, Nigeria; and NHA denotes National Hospital Abuja in Abuja, Nigeria
a Adjusted risk ratios were derived using a generalized linear model with a binomial outcome and log link function. All variables are adjusted for all variables in the column